Game-Changers: mRNA Vaccines Boost Cancer & Eye Therapies

Two groundbreaking medical advancements are reshaping patient care globally. First, researchers have reported that receiving mRNA vaccines cancer patients undergoing immunotherapy significantly improves survival. Simultaneously, an experimental retinal implant is reversing a common form of age-related blindness, offering renewed hope to millions. These developments highlight the rapid progress in both oncology and ophthalmology, promising better futures for patients.

Improved Cancer Survival with mRNA Vaccines

Cancer patients who received mRNA-based COVID vaccines within 100 days of starting widely used immunotherapies were twice as likely to be alive three years later, researchers announced. This compelling finding comes from a study involving patients with advanced non-small cell lung cancer (NSCLC) and metastatic melanoma. For example, among 180 NSCLC patients who received an mRNA vaccine from Moderna or Pfizer/BioNTech, the median survival was 37.33 months. Conversely, 704 unvaccinated cancer patients had a median survival of just 20.6 months.

Moreover, for patients with metastatic melanoma, a highly aggressive form of skin cancer, more than half of the 43 vaccinated individuals were still alive. In contrast, half of the 167 unvaccinated melanoma patients had died by 26.67 months. Dr. Adam Grippin of The University of Texas MD Anderson Cancer Center expressed enthusiasm about these findings, noting that widely available, low-cost vaccines could dramatically enhance the effectiveness of certain immune therapies.

Understanding the Mechanism of Action

Earlier laboratory experiments offered insight into how mRNA vaccines enhance cancer drugs like Merck’s Keytruda, which are known as immune checkpoint inhibitors. The vaccines appear to induce cancer cells to increase production of the PD-L1 protein, a target for these drugs. Therefore, when immune checkpoint inhibitors block PD-L1, the immune system can more effectively recognize and attack cancer cells.

The survival benefits observed were particularly pronounced in patients whose tumors were not expected to respond well to immunotherapy due to low initial production of PD-L1. These patients experienced a nearly five-fold improvement in three-year overall survival rates after receiving a COVID vaccine. These consistent findings were presented at the 2025 European Society for Medical Oncology Congress in Berlin, even after accounting for factors such as vaccine manufacturer, number of doses, and treatment location.

Breakthrough in Age-Related Macular Degeneration Treatment

In another significant medical advance, an experimental device implanted in the eye, wirelessly connected to special eyeglasses, reversed a common cause of blindness in most patients studied. Researchers reported these findings at a medical meeting, along with publication in The New England Journal of Medicine. This innovative system, known as Science Corp’s PRIMA System, offers a new treatment for age-related macular degeneration (AMD), a leading cause of irreversible blindness.

Among 32 older volunteers who were legally blind from AMD and received the PRIMA System implant, a remarkable 80% could read letters, numbers, and words soon after the procedure and at a one-year follow-up examination. Patients experienced an average improvement of about 25 letters on the standard eye chart.

How the Retinal Implant Works

The PRIMA implant system is sophisticated. It includes specialized glasses and a pocket processor featuring zoom functionality and other digital enhancements. This technology brings even small print, fonts less than 8 points, into focus. The glasses’ camera captures images and transmits visual information to the pocket processor. Subsequently, processed information returns to the glasses and projects onto the implant using near-infrared light. The implant then converts this infrared light into electrical impulses, stimulating the patient’s few remaining functional retinal cells, which then send the signal to the optic nerve.

Importantly, the implant restores central vision while preserving natural peripheral vision, enabling patients to merge both prosthetic and peripheral vision for a more complete visual experience. While 19 patients experienced side effects such as eye pressure, retinal tears, and blood under the retina, most were mild or moderate and resolved within two months. Senior author Dr. Jose-Alain Sahel from the University of Pittsburgh School of Medicine affirmed that the benefits far outweighed the adverse effects, highlighting the system’s ability to help patients read words and sentences again while retaining peripheral vision.

Frequently Asked Questions

Q1: How do mRNA COVID vaccines benefit cancer patients receiving immunotherapy?

A1: mRNA COVID vaccines appear to enhance the effectiveness of immunotherapy drugs by prompting cancer cells to increase production of the PD-L1 protein, making them more susceptible to immune checkpoint inhibitors. This immune activation helps the body’s immune system to better recognize and attack cancer cells, leading to improved survival rates.

Q2: What types of cancer showed improved outcomes with mRNA vaccine use?

A2: The study primarily focused on patients with advanced non-small cell lung cancer (NSCLC) and metastatic melanoma. Both groups demonstrated significantly improved three-year survival rates when they received an mRNA COVID vaccine around the time of starting immunotherapy.

Q3: What is the PRIMA System and how does it help patients with age-related macular degeneration (AMD)?

A3: The PRIMA System is an experimental retinal implant designed to restore central vision in patients with advanced age-related macular degeneration. It works by converting images captured by special glasses into electrical impulses that stimulate remaining functional retinal cells, allowing patients to regain the ability to read letters, numbers, and words while preserving their peripheral vision.

References

mRNA COVID vaccines appear to make immunotherapy cancer drugs work better – ETHealthworld
Cancer patients on immunotherapy live twice as long with mRNA Covid vaccines study – vertexaisearch.cloud.google.com
COVID mRNA vaccines may be able to train immune system to attack cancer cells, boost survival | CIDRAP – vertexaisearch.cloud.google.com
Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer – UF Health – vertexaisearch.cloud.google.com
Retinal Implant Restores Central Vision in Patients with Age-Related Macular Degeneration – vertexaisearch.cloud.google.com
The New England Journal of Medicine Reports Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration – vertexaisearch.cloud.google.com
Cancer patients who got a COVID vaccine lived much longer – ScienceDaily – vertexaisearch.cloud.google.com
Cancer Study Links COVID Shots to Longer Survival – MedPage Today – vertexaisearch.cloud.google.com
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy | MD Anderson Cancer Center – vertexaisearch.cloud.google.com
Revolutionary implant allows patients with dry AMD to read again – Macular Society – vertexaisearch.cloud.google.com
Eye prosthesis is the first to restore sight lost to macular degeneration – Stanford Medicine – vertexaisearch.cloud.google.com
Subretinal implant partially restores vision in AMD patients – Inserm Newsroom – vertexaisearch.cloud.google.com
mRNA Covid-19 Vaccines May Boost Effectiveness of Immunotherapy in Lung Cancer and Melanoma Patients – GeneOnline News – vertexaisearch.cloud.google.com

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.